|
| |
| The Tel Aviv Stock Exchange (TASE) and NASDAQ are holding an investor conference highlighting life science industries on December 6, 2010. The conference will be held in NASDAQ’s Times Square headquarters and will be launched with an opening bell ceremony featuring the CEOs of 14 Israeli biomed companies as well as the heads of NASDAQ and the TASE. The aim of the conference is to introduce leading NASDAQ and TASE-traded Israeli biomed companies with US investors which specialize in life sciences.
Comprised primarily of small-cap biotech and medical device companies, “Biomed” is a one of the most challenging and fastest growing sectors in Israel’s capital market. More than 50 biomed companies trade on TASE, some of which are dually-listed on US national markets as well. The conference will alert US investors as to the tremendous potential engendered in the companies operating in this space.
14 Israeli companies will take part in the conference in various plenary presentations, professional panels and “one-on-one” meetings. These include:
• Aposense – therapeutic and diagnostic drug development
• BiolineRX – drug development
• Brainsway – non-invasive treatment of brain disorders
• Clal Biotechnology Industries – life sciences investment company
• Compugen – drug and diagnostic candidate discovery
• D-Medical Industries – drug delivery systems
• D-Pharm – biopharmaceuticals for brain disorders
• Evogene – agriculture and bio-fuel
• Hadasit Bio-Holdings – investment in early-stage Hadassah Hospital-based companies
• Itamar Medical – non-invasive diagnostic devices
• Kamada – Biopharmaceuticals
• Mazor Robotics –advanced surgical devices
• Prolor Biotech – long-acting therapeutic proteins
• Protalix Biotherapeutics – recombinant protein biopharmaceuticals
The conference will also include a guest lecture by Jonathan Silverstein, a partner in OrbiMed, one of the world’s largest life science investment management company with a portfolio valued at US $5 billion. Silverstein specializes in life science sector investments and in complex transactions involving small-cap biotechnology and medical device companies.
Ester Levanon, TASE CEO: “The 51 biomed companies currently trading on the Tel Aviv Stock Exchange has rendered it one of the leading exchanges in this sector. We feel that we have an obligation to assist TASE-listed technology companies gain exposure among foreign investors. This Biomed conference, co-sponsored by TASE and NASDAQ underscores the cooperation between the two exchanges and testifies to our commitment to Israel’s hi-tech industries and the potential they hold for investors both in Israel and abroad.”
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
